Click here for flyer
(Taken from cc-TDI.org)Ā Dr. Keller’sĀ research focuses on the development of more effective, less toxic therapies for childhood cancers. His special interest is advanced disease that has spread beyond the initial location of the cancer. Charles co-chairs the brain tumor developmental therapeutics committee (CNS-DVL) of the Childrenās Oncology Group and is a member of the soft tissue sarcoma (STS) committee of Childrenās Oncology Group, and recently completed a 5-year rotation as a Standing Member of the National Cancer Institute NCI-I Study Section. Charles attended Tulane University where he received a degree in Biomedical Engineering prior to attending Baylor College of Medicine where he received his M.D. degree. After completing his internship and residency in Pediatrics at Texas Children’s Hospital, Charles trained in Pediatric Hematology-Oncology at the University of Utah and with 2007 Nobel laureate, Mario Capecchi. Charles has authored over 80 scientific publications and is a recognized expert in the biology of childhood sarcomas and the pre-clinical investigation of childhood cancers.
Dr. Keller’s talk this Thursday at the TransAmerica and WGF Financial Group in Encino, CA, focuses on a current research project for diffuse intrinsic pontine glioma (DIPG), arguably the most devastating pediatric malignancy, involving microchip technology poised to facilitate determining the most probable efficacious combination of promising medicines for DIPG within the time-span of a weekend. Ā The median survival time for DIPG is 9 months with radiation therapy, hence the urgency of the need for this research and the fact that time is not a luxury these children have. Ā Dr. Keller’s presentation is an unique opportunity to learn about pre-clinical research and it’s development into actual therapies for children with cancer. Ā The event begins at 6pm; click the image below for location for other details.
